Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. - Wikidata - awgldk - TriplyDB

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

http://www.wikidata.org/entity/Q34663298

about

The TRPA1 channel in migraine mechanism and treatment Advances in pharmacological treatment of migraine The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs Prophylactic pharmacological treatment of chronic daily headache.One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010.Neurogenic inflammation in the context of migraine.Modelling headache and migraine and its pharmacological manipulation Involvement of substance P and the NK-1 receptor in human pathology.RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception.Finding new drug targets for the treatment of migraine attacks.Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain Substance P in heart failure: the good and the bad.Migraine pathophysiology.Migraine: new treatment options from molecular biology.Verisimilitude (or "truthlikeness") as an alternative to pro and cons: migraine and cluster headache mechanisms.Experimental migraine models and their relevance in migraine therapy.New migraine and pain research.Medullary pain facilitating neurons mediate allodynia in headache-related pain Animal models of headache: from bedside to bench and back to bedside.Neurokinin-1 receptor antagonists: a comprehensive patent survey.Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine.Animal migraine models for drug development: status and future perspectives.Efficacy and mechanism of anticonvulsant drugs in migraine.Role of cortical spreading depression in the pathophysiology of migraine.Animal models of chronic migraine.Therapeutic prospects for migraine: can paradise be regained?Pathophysiology of Migraine: A Disorder of Sensory Processing.Imaging drugs with and without clinical analgesic efficacy.Trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation.Triptan-induced latent sensitization: a possible basis for medication overuse headache.Neuropeptide localization in the "migraine generator" region of the human brainstem.Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats.An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres.Octreotide is not effective in the acute treatment of migraine.Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo.The effects of ibuprofen and the neurokinin-1 receptor antagonist GR205171A on Fos expression in the ferret trigeminal nucleus following tooth pulp stimulation.Neurovascular mechanisms of migraine and cluster headache.Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients.

P2860

Q27016641-709326FE-935C-43D7-B456-74AB6067D81F Q28192002-B6285BD4-FA1B-4C94-B0AA-D2F9EB273776 Q28345449-B981146B-B4D4-4F6D-BF39-555A45D20B47 Q33888684-7FB8F560-4157-480C-BFDA-C70D8124E790 Q34180539-F71379B8-AAE4-4E8C-88A8-53480C18133B Q34218309-F353518E-D17F-4C95-8AD7-523B39BE4507 Q34407137-08B220C0-A6F0-4801-9710-9A8AF8518FA0 Q34413850-61A1AF96-47A0-459E-B9A8-D1606818C92F Q34648375-1908422F-2263-4673-AA39-0653C0B3583C Q34720188-7CDA288C-100F-45CB-A241-E63C3FFA6DC0 Q34954050-159E7827-CD59-425F-BFE2-05D357A28C92 Q34954885-5BF67BAE-8C72-4461-8791-3B6731F6CDFF Q35670008-67B37BEE-1CBE-445E-B653-7F1617D013DF Q36099504-9EAEE70F-E1DA-44DA-A921-1E41A9CDFCEF Q36257220-9D41CD96-2B9B-43F8-8949-F4B5A6D2C35C Q36261133-47FDE227-989D-44F7-A1E8-BFB64243947F Q36474260-BE2C1C70-FF8E-429A-8F15-9A4D40FFBA77 Q36787453-0A0D4E5E-3483-4BB6-879C-46FBE8F736ED Q37409407-FCE8A3CC-9601-4A4F-AF28-3B0706FDFEEE Q37699421-051A4BC9-8641-480A-8ED9-24C3A49A5A56 Q37763716-FA855B5D-9470-4BDA-A800-7EBB3D99470E Q37858847-18D6864C-E833-4D46-9FE3-1C1E5071D934 Q38129436-177257EE-8DFD-4542-BA94-87992E331F1C Q38162801-44A33A67-47D2-49F6-95AA-529313094669 Q38185096-91CC6FFC-277F-4F7C-8F14-C1782FDF685E Q38254739-94CAA5AD-2150-4E15-97C2-5E5E3D025E17 Q38270467-C620EB69-9DC8-4C1B-87A2-98D5C4BCF7BA Q38392414-F75F78B3-BB91-4736-B6C5-C89E93E814A0 Q39127073-3FA34281-968E-440A-941E-6100E13EF52D Q39596370-86BBC2F0-003C-4815-A31E-1610A29CE27A Q42116885-8BE4AE76-BDF6-4D5E-B3FC-D45D520065DE Q43107488-56B76F61-0C0F-4F04-B85C-6B495E75899C Q43650535-40C7320A-20A5-42DF-85B8-652DC51DC499 Q43650966-4D970170-4E86-431F-BABC-F36BE08B7E37 Q44073647-00B0A04F-0B17-492F-97D0-994F7993C4DE Q45192198-4E3971CB-601F-4296-9B49-0F6B68F27B2C Q46580205-BDD129AD-9E52-436F-A966-EDB498C14BA2 Q46980234-F8CFE480-C526-40CC-87C0-B0F8DD8BB471 Q47758217-30ACB75F-EFBC-41B2-9EB5-AC8D6B156FB2 Q48495487-E1C10CA7-07C8-4DA3-ABB5-8E792FEF3339

P2860

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

http://www.wikidata.org/entity/Q34663298

description

1997 nî lūn-bûn

@nan

1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@ast

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@en

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@nl

type

label

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@ast

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@en

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@nl

prefLabel

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@ast

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@en

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@nl

P1433

Q34663298-1F1F7D23-204B-426F-97B0-00D8A67AA467

P1476

Q34663298-E9FD63ED-AADF-4D88-8B09-E529E3E8820E

P2093

Q34663298-18438333-169D-42A1-A4B7-D82BBAA137D1

Q34663298-317EBDD1-F723-4577-8090-5E4FF04188B5

Q34663298-630703E1-C0BA-4D20-9DF6-5AAA1C45A04C

Q34663298-E444B990-FFB8-4DF3-B361-3E4F48FC105B

Q34663298-F0D92200-5C9A-4BC4-8E9B-50481F483A79

Q34663298-F1AD7931-6CD2-4F39-8704-2E7508BEE0A6

P2860

Q34663298-1D2D3C24-B524-421D-9509-0D0D9D5B6E08

Q34663298-3533356F-CEB3-42B7-9827-509AD670B1A6

Q34663298-7D8DF942-8FEF-4787-9E99-6CC52583867E

Q34663298-8DE1587C-0C4C-4F36-8ADA-27CCBF94C966

Q34663298-A2FC1F97-D73A-4153-9716-9A28B81CCF91

Q34663298-B47F6CF8-0E82-45DE-A279-CE28CDF70B17

Q34663298-C4B22517-D060-4831-B923-8E96FAA6894A

Q34663298-E6399AFF-1EE0-4B15-88E0-F2E914BE37CC

Q34663298-F9E972EB-41C0-46DD-994B-E97C82EE8394

Q34663298-FDB42424-26DA-4C6F-B742-92AA3F8C3294

P304

Q34663298-C6C120B9-A1AF-459A-B908-D5C20E0C8233

P31

Q34663298-060351BD-F418-40A5-91DC-CFB8A30C9349

P356

Q34663298-5C814117-5259-4301-8458-C9A16B6CC2AD

P407

Q34663298-C4EF3684-26A9-470B-B97F-F717B8F2D4E0

P433

Q34663298-FC27F0A0-529B-42E1-A472-EFBD6F246F85

P478

Q34663298-0F1434BA-84C0-4F66-AF6F-3213586798BD

P577

Q34663298-BEDB0E34-DE74-4E17-8A74-5F1B43CED292

P698

Q34663298-047BAFC3-2F47-4B2D-83D2-559D779D1697

P921

Q34663298-5083168D-0D7B-4A7D-9B5F-6C3754154772

P356

J.1468-2982.1997.1707785.X

P1433

P1476

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study.

@en

P2093

D J Goldstein

http://www.w3.org/2001/XMLSchema#string

J R Saper

http://www.w3.org/2001/XMLSchema#string

N T Mathew

http://www.w3.org/2001/XMLSchema#string

O Wang

http://www.w3.org/2001/XMLSchema#string

R Stoltz

http://www.w3.org/2001/XMLSchema#string

S D Silberstein

http://www.w3.org/2001/XMLSchema#string

P2860

CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges

Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors.

The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater

Migraine: A vasomotor instability of the meningeal circulation.

Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine?

Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability

Calcitonin gene-related peptide is a potent inhibitor of substance P degradation.

Calcitonin Gene-related Peptide Causes Intraspinal Spreading of Substance P Released by Peripheral Stimulation.

Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space.

Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine.

P304

785-790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1468-2982.1997.1707785.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

1997-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9399010

http://www.w3.org/2001/XMLSchema#string

P921

migraine disorder